BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33455080)

  • 1. Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells.
    Meng L; Chen D; Meng G; Lu L; Han C
    FEBS Open Bio; 2021 Mar; 11(3):921-931. PubMed ID: 33455080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense.
    Zhou L; Wang F; Sun R; Chen X; Zhang M; Xu Q; Wang Y; Wang S; Xiong Y; Guan KL; Yang P; Yu H; Ye D
    EMBO Rep; 2016 Jun; 17(6):811-22. PubMed ID: 27113762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
    Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
    EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
    Guo X; Li R; Bai Q; Jiang S; Wang H
    J Cell Mol Med; 2020 Dec; 24(24):14441-14452. PubMed ID: 33145941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CircRNA_001895 promotes sunitinib resistance of renal cell carcinoma through regulation of apoptosis and DNA damage repair.
    Tan L; Huang Z; Chen Z; Chen S; Ye Y; Chen T; Chen Z
    J Chemother; 2023 Feb; 35(1):11-18. PubMed ID: 34927575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
    Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
    Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
    Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
    Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIRT5-Related Desuccinylation Modification Contributes to Quercetin-Induced Protection against Heart Failure and High-Glucose-Prompted Cardiomyocytes Injured through Regulation of Mitochondrial Quality Surveillance.
    Chang X; Zhang T; Wang J; Liu Y; Yan P; Meng Q; Yin Y; Wang S
    Oxid Med Cell Longev; 2021; 2021():5876841. PubMed ID: 34603599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
    Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
    Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
    Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity.
    Sato H; Uzu M; Kashiba T; Fujiwara T; Hatakeyama H; Ueno K; Hisaka A
    Eur J Pharmacol; 2019 Mar; 847():143-157. PubMed ID: 30689992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.
    Ruan H; Li S; Bao L; Zhang X
    Oncogene; 2020 Sep; 39(38):6113-6128. PubMed ID: 32814829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
    Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
    Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
    [No Abstract]   [Full Text] [Related]  

  • 16. QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis.
    Zhao T; Zhou Y; Wang Q; Yi X; Ge S; He H; Xue S; Du B; Ge J; Dong J; Qu L; Wang L; Zhou W
    Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34036385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis.
    Ma Y; Qi Y; Wang L; Zheng Z; Zhang Y; Zheng J
    Free Radic Biol Med; 2019 Apr; 134():458-467. PubMed ID: 30703481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
    Gobe GC; Ng KL; Small DM; Vesey DA; Johnson DW; Samaratunga H; Oliver K; Wood S; Barclay JL; Rajandram R; Li L; Morais C
    Biochem Biophys Res Commun; 2016 Apr; 473(1):47-53. PubMed ID: 26995091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.